“Good, better, best—never let it rest—until your good isbetter and your better is best,” 这句谚语也许是对wet-AMD疾病治疗领域最好的描述,前进的步伐永不停歇。 参考文献 Profile ofconbercept in the treatment of neovascular age-related macular degeneration. Fusion proteins fortreatment of retinal...
1.1 AMD Age-related macular degeneration (AMD) is a leading cause of blindness among industrialized nations and a significant source of morbidity globally (Wong et al., 2014). The pathogenesis of AMD is broadly divided into two pathways, “wet” and “dry.” Wet AMD (also known as exudative...
age‐related macular degenerationmicrofluidic platformsorgans‐on‐chipsouter blood retinal barrierRPE‐choroid complexIn article number 1700028, Noo Li Jeon, Jeong Hun Kim, and co‐workers describe a unique organotypic eye‐on‐a‐chip model that mimics the retinal pigment epithelium (RPE)–choroid ...
Home Care Tips for Wet Age-Related Macular Degeneration Discover practical tips to manage wet AMD at home, from better lighting to using adaptive tools for daily tasks. Could Blood Pressure Medication Increase Your Wet AMD Risk? Explore the potential link between blood pressure medicine and an inc...
Dr Khanani begins with two studies on intravitreal gene therapies, a class of medication in development that promises to treat patients with a single dose, thereby reducing the treatment burden associated with wet AMD. The first study examined whether lowering the dose of ixoberogene soroparvovec ...
Themaculais the part of the retina (the back of your eye) you need to see straight ahead. When you have age-related macular degeneration (AMD), the macula is damaged. AMD comes in two types: wet and dry. The dry type is more common than the wet type. ...
AMD is a leading cause of vision loss in people 60 and older. There is no cure for wet AMD, but Eylea is a proven effective treatment. Eylea is the brand name for the generic medication aflibercept. It is an FDA-approved prescription medicine administered by anophthalmologistby injection into...
In the treatment of neovascular age-related macular degeneration (AMD), vascular endothelial growth factor (VEGF) has emerged as a key target of therapy. Currently, patients with neovascular AMD are treated with monthly intravitreal injections of anti-VEGF medications. Aflibercept is a novel recombinan...
Axitinib injectable suspension (CLS-AX) achieved all primary and secondary outcomes in the treatment of neovascular (wet) age-related macular degeneration (AMD), according to topline data from the Phase 2b ODYSSEY trial.1 Announced by Clearside Biomedical, on October 9, 2024, suprachoroidal CLS-...
study published inOphthalmologyhighlighted the delicate balancing act of medication management for the prevention of life-threatening cardiac events and sight-threatening diseases when it reported that warfarin significantly increased the risk of conversion to neovascular age-related macular degeneration (AMD)...